Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Gliatech (GLIA) -- Ignore unavailable to you. Want to Upgrade?

To: PHILLIP FLOTOW who wrote (659)	3/1/1999 9:43:00 AM
From: scaram(o)uche	Respond to of 2001

Phil: Thanks for the heads-up. We already knew, from the conference call, that the single-dose portion was positive, and the multiple-dose portion isn't completed. We also knew that a report on the single-dose portion was due about a week ago. So.... headline is probably accurate, but.... it doesn't mean that we'll be canceling the phase II and III testing and going direct to market. ;-) Rick

To: PHILLIP FLOTOW who wrote (659)	3/1/1999 12:07:00 PM
From: Asymmetric	Read Replies (1) \| Respond to of 2001

Gliatech Histamine Antagonist Shows Positive Phase I Results Dow Jones Newswires -- March 1, 1999 CLEVELAND --Gliatech said data from a Phase I rising single- dose clinical study of its GT2331 histamine H3 antagonist, for the potential treatment of Alzheimer's, Attention Deficit Hyperactivity Disorder and sleep disorders, demonstrated positive results. In a press release Monday, the therapeutic products maker said the Phase I study of GT2331 was a double-blind, randomized, placebo-controlled trial designed to investigate the safety, tolerability and pharmacokinetic profile of GT2331 in healthy volunteers. Gliatech said several doses of GT2331 or placebo were administered, and said no serious adverse events occurred at the doses evaluated, with no clinically significant blood chemistry or hematological differences in treated and controlled patients. The company said pharmacokinetic analysis indicated GT2331 blood levels higher than those expected for pharmacological effect, and said GT2331 exhibited a plasma half-life which should allow for once-daily dosing. Gliatech said based on the favorable Phase I results, the company initiated a rising multiple dose study, in which several doses of GT2331 will be administered for two weeks to healthy volunteers. (Richard H - So far so good!) Peter